Related Experiment Video
Updated: Dec 24, 2025
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction
Abstract:
Although kinase-targeted drugs have achieved significant clinical success, they are frequently subject to the limitations of drug resistance, which has become a primary vulnerability to targeted drug therapy. Therefore, deciphering resistance mechanisms is an important step in designing more efficacious, antiresistant drugs. Here we studied two FDA-approved kinase drugs: Crizotinib and Ceritinib, which are first- and second-generation anaplastic lymphoma kinase (ALK) targeted inhibitors, to unravel drug-resistance mechanisms. We used an on-the-fly, function-site interaction fingerprint (on-the-fly Fs-IFP) approach, combining binding free-energy surface calculations with the Fs-IFPs. Establishing the potentials of mean force and monitoring the atomic-scale protein-ligand interactions, before and after L1196M-induced drug resistance, revealed insights into drug-resistance/antiresistant mechanisms. Crizotinib prefers to bind the wild-type ALK kinase domain, whereas Ceritinib binds more favorably to the mutated ALK kinase domain, in agreement with experimental results. We determined that ALK kinase-drug interactions in the region of the front pocket are associated with drug resistance. Additionally, we find that the L1196M mutation does not simply alter the binding modes of inhibitors but also affects the flexibility of the entire ALK kinase domain. Our work provides an understanding of the mechanisms of ALK drug resistance, confirms the usefulness of the on-the-fly Fs-IFP approach, and provides a practical paradigm to study drug-resistance mechanisms in prospective drug discovery.
Insights
Understanding drug resistance in anaplastic lymphoma kinase (ALK) inhibitors like Crizotinib and Ceritinib is crucial. This study reveals how mutations affect drug binding and kinase flexibility, paving the way for new antiresistant therapies.
Area of Science:
- Oncology
- Pharmacology
- Computational Chemistry
Background:
- Kinase-targeted drugs show clinical success but face drug resistance.
- Anaplastic lymphoma kinase (ALK) inhibitors like Crizotinib and Ceritinib are vital in cancer therapy.
- Drug resistance is a major challenge limiting the efficacy of targeted therapies.
Purpose of the Study:
- To investigate the molecular mechanisms of drug resistance in anaplastic lymphoma kinase (ALK) inhibitors.
- To analyze the binding interactions of Crizotinib and Ceritinib with wild-type and resistant ALK.
- To evaluate the utility of the on-the-fly function-site interaction fingerprint (on-the-fly Fs-IFP) approach in studying resistance.
Main Methods:
- Utilized an on-the-fly Fs-IFP approach combined with binding free-energy surface calculations.
- Calculated potentials of mean force to monitor atomic-scale protein-ligand interactions.
- Compared interactions before and after L1196M mutation-induced drug resistance.
Main Results:
- Crizotinib preferentially binds wild-type ALK, while Ceritinib favors the mutated ALK kinase domain.
- ALK kinase-drug interactions in the front pocket region are linked to drug resistance.
- The L1196M mutation impacts inhibitor binding modes and overall ALK kinase domain flexibility.
Conclusions:
- Elucidated key mechanisms underlying ALK inhibitor drug resistance.
- Confirmed the effectiveness of the on-the-fly Fs-IFP method for resistance studies.
- Provided a framework for future drug discovery and development of antiresistant agents.
